Look how far we have come in #diabetes technology and there is still a lot more to go #AACE2022. #CGM technology has been a game changer and the accuracy continues to improve with each generation
So what's new in the pipeline for #diabetes technology? Let me tell you starting with #dexcom G7. It will be smaller with a better MARD, better warm up and ALL-IN-ONE applicator and transmitter! Just pending FDA review #AACE2022#endotwitter#medtwitter
#FreeStyleLibre 2 is already out with better MARD, and q1minute sensor readings. Libre 2 going through FDA review will be much smaller (size of a penny!)
#Eversense recently approved for 6 months of implantable use. Best MARD so far of the cgms. ONly one calibration daily is needed. On body alerts
Tandem w/ recent FDA clearance for remote bolusing. This will be a game changer for pediatric population and parents managing them, right @askewed? I'm excited about the tubeless pump in the pipeline by tandem
#Omnipod 5 is out with it's hybrid closed loop system with adjustable targets. It's still a limited release but those on the interest list can upgrade through their podder account.
#Medtronic 780G already available in Europe and soon to come to US. No more calibrations outside of the first day. Two targets and extended infusion set approved! Awaiting FDA approval
#ILet In the pipeline and undergoing clinical trials -- a fully automatic bionic pancreas -- insulin with glucagon. This will be a game changer for those who live with #diabetes. I can't wait
There are many options for #diabetes technology. Choose which one is right for your patient based on the different features. Here are some comparison charts to help you decide. Thanks @ArchanaSadhu for the great slides!
Let's hear The Evidence For and Against Combination #Thyroid Hormone therapy by Dr. Bianco #AACE2022#Endotwitter. This conversation is controversial here are some of the main slides
Patient's on Lt4 reporting a lot of residual symptoms in energy, cognition
Normal physiology the majority of thyroid hormone production is T4 (16:1 T4:T3) and gets converted peripherally to T3 (5mcg made in thyroid, 25mcg made peripherally)
Now to talk about Phosphatonins and #phosphorus metabolism/bone disease by Dr. Kumar moderated by @sfeirjad...I'm ready to learn since admittedly I know little of this #AACE2022#Endotwitter#bone
Why bother about phosphorus? Well it plays many roles in cellular signaling and maintenance of membrane structure of #bone. Low concentrations associated with rhabdo, decreased cardiac function and bone dysfunction (#osteomalacia, #rickets). low and high phos causes bone disease
High Phos Concentrations are Associated with CV Disease and Excess Mortality in CRF and decreasing levels reduces CV mortality
#NAFLD has effects on other conditions including DM, CVD, CKD etc due to increased hyperinsulinemia, insulin resistance, proinflammatory factors etc
How do we screen for #NAFLD and find the ones with fibrosis? A lot will be missed if just checking transaminases. FIB-4 and NFS is a better screening tool
NAFLD is a spectrum that includes NASH. First rule out secondary causes.
Difference between NAFL and NASH? NAFL is just the accumulation of fat w/o ballooning or much inflamation. NASH has hepatocyte changes from ballooning and inflammation. IIt is staged also based on fibrosis (F0-F4)